Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Peter Clark, MA, MD, FRCP: A Payer Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement

Oct

15

Today In Oncology

Amyloidosis: Novel Treatments Could Improve Poor Outcomes

ASCO and WHO Formalize Partnership

FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer

Short-Course SBRT Better Preserves Physical Function Before Pancreatic Cancer Surgery

Chronic Immune-Related Adverse Events Common After Adjuvant Anti–PD-1 Therapy for Melanoma

Advertisement

© 2026 HSP News Service, L.L.C.